|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-5-7
|
|
pubmed:abstractText |
We performed a randomized trial on pegylated interferon alfa-2a (Peg-IFNalpha) monotherapy vs Peg-IFNalpha and ribavirin in non-cirrhotic liver transplant recipients with recurrent hepatitis C.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0168-8278
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1009-17
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17328985-Adult,
pubmed-meshheading:17328985-Aged,
pubmed-meshheading:17328985-Antiviral Agents,
pubmed-meshheading:17328985-Female,
pubmed-meshheading:17328985-Hepatitis C,
pubmed-meshheading:17328985-Humans,
pubmed-meshheading:17328985-Interferon-alpha,
pubmed-meshheading:17328985-Liver Transplantation,
pubmed-meshheading:17328985-Male,
pubmed-meshheading:17328985-Maximum Tolerated Dose,
pubmed-meshheading:17328985-Middle Aged,
pubmed-meshheading:17328985-Polyethylene Glycols,
pubmed-meshheading:17328985-Recombinant Proteins,
pubmed-meshheading:17328985-Recurrence,
pubmed-meshheading:17328985-Ribavirin,
pubmed-meshheading:17328985-Time Factors,
pubmed-meshheading:17328985-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.
|
|
pubmed:affiliation |
Hepatology Unit, Tor Vergata University, Rome, Italy. angelico@med.uniroma2.it
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
